| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.027 | 0.9 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |